Prognostic value of a simplified score based on routine parameters in patients with hepatocellular carcinoma treated with systemic therapies: a retrospective cohort study
Authors:
- Leonardo G. Da FonsecaLFLeonardo G. Da Fonseca
- Thamires Haick Martins da SilveiraTSThamires Haick Martins da Silveira
- Victor Junji YamamotoVYVictor Junji Yamamoto
- Marina Acevedo Zarzar de MeloMMMarina Acevedo Zarzar de Melo
- Lucas Takeshi IkeokaLILucas Takeshi Ikeoka
- Pedro Henrique Shimiti HashizumePHPedro Henrique Shimiti Hashizume
- Jorge SabbagaJSJorge Sabbaga
Open Access
- 1 October 2025
- journal article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (5) , 2262-2273
Abstract
Background: The systemic treatment landscape for advanced hepatocellular carcinoma (HCC) has evolved from tyrosine kinase inhibitors, such as sorafenib (SOR), to immune checkpoint inhibitor-based combinations (IO). Despite these advances, there is a lack of simple, objective tools to stratify patient prognosis in clinical practice. While several laboratory parameters are known to correlate with outcomes, their combined utility across treatment types remains unclear. We aimed to evaluate the prognostic value of commonly available biomarkers and to develop a simplified score applicable to both SOR- and IO-treated patients. Methods: This retrospective cohort study analyzed patients with advanced or intermediate-stage HCC treated with first-line systemic therapy at a single center in Brazil from 2009 to 2024. Patients were stratified into a SOR cohort and an IO cohort. Baseline variables included demographics and biochemical markers. We assessed the association between survival and three baseline biomarkers: alpha-fetoprotein (AFP), albumin-bilirubin (ALBI) grade, and neutrophil-to-lymphocyte ratio (NLR). A prognostic score was developed in the SOR cohort by assigning one point to each adverse factor: AFP ≥200 ng/mL, ALBI grade 2–3, and NLR ≥3. Overall survival (OS) was estimated by the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were derived from Cox regression models. Results: The study included 440 patients in the SOR cohort and 32 in the IO cohort. In the SOR cohort. Most patients in both cohorts were Child-Pugh A, PS 0–1 and hepatitis C was the predominant etiology. AFP ≥200 ng/mL (Pvs. 2–3 points had significantly different OS (HR 2.2; 95% CI: 1.1–4.9; P=0.04). Conclusions: This simplified prognostic score, based on three routine laboratory parameters, stratifies survival outcomes in HCC patients receiving either sorafenib or immunotherapy. While further validation is needed in larger and more diverse populations, this tool may support individualized clinical counseling and risk-adapted trial design.Keywords
This publication has 40 references indexed in Scilit:
- Tumor-Derived α-Fetoprotein Impairs the Differentiation and T Cell Stimulatory Activity of Human Dendritic CellsThe Journal of Immunology, 2014
- Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenibMedical Oncology, 2014
- Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patientsProceedings of the National Academy of Sciences, 2014
- The Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Advanced Hepatocellular Carcinoma Receiving SorafenibAsian Pacific Journal of Cancer Prevention, 2013
- The integration of T cell migration, differentiation and functionNature Reviews Immunology, 2013
- Accessories to the Crime: Functions of Cells Recruited to the Tumor MicroenvironmentCancer Cell, 2012
- Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression statusMedical Oncology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in CancerThe Journal of Immunology, 2001
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982